Regeneron Pharmaceuticals/ US75886F1075 /
| 2024-12-20 9:59:50 PM | Chg. - | Volume | Bid10:25:01 PM | Ask10:25:01 PM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 702.03USD | - | 21,325 Turnover: 5.06 mill. |
-Bid Size: - | -Ask Size: - | 77.13 bill.USD | - | 18.94 |
Assets
| 2012 US GAAP in mill. USD |
2013 US GAAP in mill. USD |
2014 US GAAP in mill. USD |
2015 US GAAP in mill. USD |
2016 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Property and Equipment | 379.9000 | 527 | 974.3090 | 1,594.1200 | 2,083.4210 | ||||||
| Intangible Assets | - | - | - | - | - | ||||||
| Long-Term Investments | - | - | 460.1540 | 632.1620 | 864.2600 | ||||||
| Fixed Assets | - | - | 1,704.3660 | 2,694.0370 | 3,793.2780 | ||||||
| Inventories | 0.0000 | 70.4000 | 128.8610 | 238.5780 | 399.3560 | ||||||
| Accounts Receivable | 693.1000 | 891.8000 | 739.3790 | 1,152.4890 | 1,343.3680 | ||||||
| Cash and Cash Equivalents | 230.3000 | 535.6000 | 648.7190 | 809.1020 | 535.2030 | ||||||
| Current Assets | 1,206 | 1,796.9000 | 2,167.4610 | 2,915.0950 | 3,180.1880 | ||||||
| Total Assets | 2,080.5000 | 2,951 | 3,871.8270 | 5,609.1320 | 6,973.4660 | ||||||
Liabilities
| 2012 US GAAP in mill. USD |
2013 US GAAP in mill. USD |
2014 US GAAP in mill. USD |
2015 US GAAP in mill. USD |
2016 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 38.9000 | 61.9000 | - | - | - | ||||||
| Long-term debt | - | - | 146.7730 | 362.9190 | 351.5690 | ||||||
| Liabilities to Banks | - | - | - | - | - | ||||||
| Provisions | - | - | - | - | - | ||||||
| Liabilities | 835.1000 | 998.9000 | 1,329.5020 | 1,954.2950 | 2,524.2210 | ||||||
| Share Capital | .1000 | .0990 | .1020 | .1060 | .1080 | ||||||
| Total Equity | 1,245.4000 | 1,952.1000 | 2,542.3250 | 3,654.8370 | 4,449.2450 | ||||||
| Minority Interests | - | - | - | - | - | ||||||
| Total liabilities equity | 2,080.5000 | 2,951 | 3,871.8270 | 5,609.1320 | 6,973.4660 | ||||||
Income Statement
| 2012 US GAAP in mill. USD |
2013 US GAAP in mill. USD |
2014 US GAAP in mill. USD |
2015 US GAAP in mill. USD |
2016 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 1,378.5000 | 2,104.7000 | 2,819.5570 | 4,103.7280 | 4,860.4270 | ||||||
| Depreciation (total) | - | - | - | - | - | ||||||
| Operating Result | 457.7000 | 760 | 838.4310 | 1,251.9160 | 1,330.7410 | ||||||
| Interest Income | -45.3000 | -46.4000 | -37.3720 | -14.2410 | -7.1950 | ||||||
| Income Before Taxes | 414.4000 | 713.4000 | 775.7470 | 1,225.0970 | 1,329.8150 | ||||||
| Income Taxes | -335.8000 | 289 | -427.6730 | -589.0410 | -434.2930 | ||||||
| Minority Interests Profit | - | - | - | - | - | ||||||
| Net Income | 750.3000 | 424.4000 | 348.0740 | 636.0560 | 895.5220 | ||||||
Per Share
Cash Flow
| 2012 US GAAP in mill. USD |
2013 US GAAP in mill. USD |
2014 US GAAP in mill. USD |
2015 US GAAP in mill. USD |
2016 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow from Operating Activities | -74.6000 | 583.6000 | 743.1570 | 1,330.7800 | 1,473.3960 | ||||||
| Cash Flow from Investing Activities | -81.1000 | -355.5000 | -420.7770 | -907.6010 | -1,046.9040 | ||||||
| Cash Flow from Financing | -97.6000 | 77.1000 | -209.2690 | -262.7960 | -700.3910 | ||||||
| Decrease / Increase in Cash | -253.3000 | 305.3000 | 113.1110 | 160.3830 | -273.8990 | ||||||
| Employees | 1,950 | 2,340 | 2,925 | 4,300 | 5,400 | ||||||
